Original Article
Brief Report
A Dystroglycan Mutation Associated with Limb-Girdle Muscular Dystrophy
N Engl J Med 2011; 364:939-946March 10, 2011DOI: 10.1056/NEJMoa1006939
- Abstract
Dystroglycan, which serves as a major extracellular matrix receptor in muscle and the central nervous system, requires extensive O-glycosylation to function. We identified a dystroglycan missense mutation (Thr192→Met) in a woman with limb-girdle muscular dystrophy and cognitive impairment. A mouse model harboring this mutation recapitulates the immunohistochemical and neuromuscular abnormalities observed in the patient. In vitro and in vivo studies showed that the mutation impairs the receptor function of dystroglycan in skeletal muscle and brain by inhibiting the post-translational modification, mediated by the glycosyltransferase LARGE, of the phosphorylated O-mannosyl glycans on α-dystroglycan that is required for high-affinity binding to laminin.
Media in This Article
Figure 1
Identification of a DAG1 Missense Mutation in a Woman with Limb-Girdle Muscular Dystrophy, and In Vitro Biochemical Characterization of the Encoded Protein.Figure 2
Biochemical and Physiological Skeletal-Muscle Phenotypes of Disease in Gene-Targeted Mice with the Same Dystroglycan Mutation as the Patient.Article Activity
- Article
Muscular dystrophies are genetic diseases characterized by weakness and progressive degeneration of skeletal muscle. The transmembrane protein dystroglycan, which is ultimately cleaved into an α and a β component, is a key link between the cytoskeleton and extracellular-matrix proteins that bear laminin globular domains (e.g., laminin, agrin, and neurexin).1,2 The mucin domain of α-dystroglycan is modified with numerous O-linked oligosaccharides that are essential for its normal function as an extracellular-matrix receptor in various tissues, including skeletal muscle and brain.2,3 Hypoglycosylation of α-dystroglycan and a consequent reduction of α-dystroglycan binding to extracellular-matrix proteins are observed in patients with the Walker–Warburg syndrome, muscle–eye–brain disease, Fukuyama-type congenital muscular dystrophy, congenital muscular dystrophy types 1C and 1D, and limb-girdle muscular dystrophy 2I.2 To date, genes encoding six putative and known glycosyltransferases (POMT1, POMT2, POMGnT1, LARGE, FKTN, and FKRP) have been shown to be responsible for approximately 50% of cases of these diseases, which are collectively referred to as secondary dystroglycanopathies4-11 and which often feature brain abnormalities as well as muscular dystrophy. Despite recent advances in our understanding of the molecular mechanisms underlying secondary dystroglycanopathies, it remains unclear whether dystroglycan is the only target of these enzymes or whether other substrates contribute to the pathogenesis of these diseases.
Dystroglycan is known to be modified with several classes of oligosaccharides: N-glycans, mucin-type O-glycans, and O-mannosyl glycans.2 The O-mannosyl glycans are thought to be responsible for dystroglycan's ligand-binding activity because the POMT1–POMT2 protein complex catalyzes the transfer of mannose to serine or threonine residues by means of an O-linkage.2 We recently reported that maturation of α-dystroglycan to its laminin-binding form requires a novel biosynthetic pathway involving phosphorylation on O-mannosyl glycans and that LARGE is crucial for further modification of phosphorylated O-mannosyl glycans on α-dystroglycan.12
Here we report a missense mutation in the dystroglycan-encoding gene, DAG1, in a patient with limb-girdle muscular dystrophy and cognitive impairment. Our studies revealed that this substitution interferes with LARGE-dependent maturation of phosphorylated O-mannosyl glycans on α-dystroglycan and leads to the disease-causing defect of α-dystroglycan binding to laminin.
Methods
Clinical Information
The patient initially received a diagnosis of limb-girdle muscular dystrophy with mental retardation.13 Clinical data regarding this patient have been reported elsewhere.14 (See also the Supplementary Appendix, available with the full text of this article at NEJM.org.) This study was approved by the institutional review board at Hacettepe University, and written informed consent was obtained from the patient's guardians.
Biochemical Analysis
Biochemical analyses, including Western blotting, laminin-binding assays, and protein pull-down assays, were carried out as previously described.3,15 (For details about the cell-culture and biochemical methods used, see the Supplementary Appendix.)
Mouse Model
Protocols for generating a knock-in mouse model harboring a mutation equivalent to that in our patient, as well as animal care and animal procedures, were approved by the University of Iowa Animal Care and Use Committee (see the Supplementary Appendix).
Results
We studied a Turkish patient with a relatively mild form of muscular dystrophy accompanied by cognitive impairment (see Case 2 in Dinçer et al.14). Although immunofluorescence analysis showed that α-dystroglycan was hypoglycosylated in this patient, no mutation was found in genes previously implicated in the pathogenesis of secondary dystroglycanopathies.14 Since the dystroglycan-encoding gene, DAG1, is a plausible candidate gene, we investigated whether our patient harbored a causative mutation therein. Sequencing of the coding and noncoding regions of DAG1 revealed a homozygous C-to-T missense mutation at position c.575, causing substitution of a methionine for a threonine at amino acid residue 192 (T192→M) of the protein (Figure 1AFigure 1
Identification of a DAG1 Missense Mutation in a Woman with Limb-Girdle Muscular Dystrophy, and In Vitro Biochemical Characterization of the Encoded Protein.). Both parents were heterozygous carriers of this mutated allele, and allele segregation in the family was consistent with recessive disease inheritance (Figure 1B). The mutated threonine residue is located in the α-dystroglycan N-terminal and is highly conserved across species (Figure 1C).We first assessed the effect of the newly identified α-dystroglycan mutation in vitro, with respect to expression, post-translational processing, or both. To this end, we transiently expressed the full-length wild-type and T192→M dystroglycan proteins in dystroglycan-null myoblasts. Western blotting with an antibody that recognizes functionally glycosylated α-dystroglycan (IIH6)3,15 revealed considerably lower immunoreactivity for T192→M than for wild-type dystroglycan when similar amounts of protein were expressed (Figure 1D). Biotinylation analysis revealed that the cell-surface expression of T192→M and wild-type dystroglycan was similar (Figure 1A in the Supplementary Appendix). Thus, in myoblasts, the T192→M substitution affects neither protein localization nor protein stability, but it does impair post-translational modification. A laminin-binding assay confirmed that the T192→M mutation considerably reduces the effectiveness of dystroglycan as a laminin receptor (Figure 1D, and Figure 1B and 1C in the Supplementary Appendix).
We next assessed the effect of the T192→M mutation on functional modification of α-dystroglycan in vivo by introducing a T190→M mutation (which corresponds to the human T192→M mutation) into the mouse Dag1 gene (Figure 2 in the Supplementary Appendix). Histologic analysis revealed hallmarks of muscular dystrophy, such as centrally nucleated fibers, in the mutant mice (Figure 2AFigure 2
Biochemical and Physiological Skeletal-Muscle Phenotypes of Disease in Gene-Targeted Mice with the Same Dystroglycan Mutation as the Patient., and Figure 3A and 4 in the Supplementary Appendix). Immunofluorescence and biochemical analyses showed that the mutated α-dystroglycan was expressed at the skeletal-muscle sarcolemma but that both ligand-binding activity and IIH6 reactivity at this location were considerably decreased (Figure 2B, and Figure 3B and 5 in the Supplementary Appendix). Analysis of the uptake in the diaphragm of the membrane-impermeable Evans blue dye revealed disruption of the skeletal-muscle sarcolemma in the T190→M mice after exercise (Figure 2C). The mutant mice also had marked impairment of exercise performance (e.g., reduced forelimb grip strength) (Figure 2D). Mice heterozygous for the T190→M mutation did not have obvious muscle defects at the histologic level, despite a slight reduction in functional glycosylation of α-dystroglycan (Figure 4 and Figure 6 in the Supplementary Appendix). Thus, the T190→M mutation caused skeletal-muscle abnormalities in mice that were consistent with those observed in our patient.In addition to its role in skeletal muscle, dys-troglycan is crucial for maintaining the structure and function of the brain and neuromuscular junctions.3,16-18 Western blot and laminin-overlay analyses revealed that laminin-binding activity was significantly diminished in the brains of mice with the T190→M mutation (Figure 3AFigure 3
Neuromuscular Phenotypes in Mice with the Dystroglycan Mutation.). Morphologic analysis of the neuromuscular junctions revealed that the T190→M mutation interfered with their maturation; on staining of diaphragm samples with α-Bungarotoxin conjugated with Alexa Fluor 488 (Invitrogen), which tightly binds acetylcholine receptors, the neuromuscular junctions in wild-type animals formed the expected pretzel-like structure, whereas those in the T190→M mice were round and immature (Figure 3B and 3C, and Figure 7 in the Supplementary Appendix). Consistent with impaired neuromuscular-junction maturation was the observation that the mutant mice had marked deficiencies in assays of neuromuscular function — for example, a reduction in retention time on a rotating-rod device (Figure 3D). Furthermore, although no structural abnormality was evident in the brains of the T190→M mice (an observation that was consistent with the results on magnetic resonance imaging [MRI] of the patient's brain), these mice had abnormal hind-limb clasping, a phenotype common to mouse models featuring neurologic impairment (Figure 8 in the Supplementary Appendix). Collectively, these results provide strong evidence that the mutation in the patient caused neurologic impairment as well as muscular dystrophy as a consequence of impaired α-dystroglycan post-translational modification.Dystroglycan is also expressed in cardiac muscle, where its function as an extracellular-matrix receptor is important for limiting activity-induced myocardial damage.19 Given that some patients with mutations in FKTN and FKRP have dilated cardiomyopathy,20,21 we analyzed cardiac tissue from T190→M mice. We observed no obvious signs of any pathological abnormality, such as fibrosis or uptake of Evans blue dye after exercise (Figure 9 in the Supplementary Appendix). Moreover, in contrast to the observed effects in brain and skeletal muscle, laminin-binding activity was affected only minimally in the hearts of T190→M mice (Figure 3A). Thus, it appears that normal cardiac function is maintained in T190→M knock-in mice and that the effects of the mutation on functional modification of α-dystroglycan are tissue-dependent.
Mutations in LARGE have been identified in patients with the Walker–Warburg syndrome or congenital muscular dystrophy type 1C, as well as in mice with myodystrophy (Largemyd ).9,10,22 We recently found that LARGE is essential for phosphorylated O-mannosyl glycans to mature into a form capable of binding laminin.12 We investigated the glycosylation status of T190→M α-dystroglycan by subjecting the protein to treatment with cold aqueous hydrofluoric acid, which cleaves phosphoester linkages, and to inorganic metal–affinity chromatography, which captures monoester-linked phosphorylated compounds. Hydrofluoric acid treatment clearly reduced the molecular weight of T190→M α-dystroglycan, and the beads on chromatography failed to capture T190→M α-dystroglycan, although they readily bound α-dystroglycan in samples from Largemyd animals (Figure 10 in the Supplementary Appendix). These results suggest that T190→M α-dystroglycan bears phosphorylated O-mannosyl glycans but that these moieties are not sufficiently mature to confer laminin-receptor function on α-dystroglycan.
Our findings suggest that the T192→M mutation affects LARGE-dependent modification of α-dystroglycan. A previous study showed that the dystroglycan N-terminal serves as a binding site for LARGE, an interaction that is essential for α-dystroglycan's laminin-binding activity.15 An in silico model suggested that the side chain of the methionine residue could affect the protein surface structure23 (Figure 11A in the Supplementary Appendix); accordingly, we hypothesized that the T192→M mutation abrogates the dystroglycan–LARGE interaction owing to a conformational change in the dystroglycan N-terminal. A pull-down assay with Fc-tagged α-dystroglycan mutants showed that although the wild-type protein bound to LARGE, variants harboring the T192→M mutation did not (Figure 11B and 11C in the Supplementary Appendix). These findings support the notion that the T192→M mutation in dystroglycan dramatically impairs the interaction between α-dystroglycan and LARGE, leading to incomplete post-translational modification of α-dystroglycan.
Discussion
Although genes responsible for O-glycosylation–dependent muscular dystrophy (i.e., dystroglycanopathy) have been identified, the molecular mechanisms whereby mutations therein lead to impaired skeletal-muscle and brain function remain elusive — in part because defects in dystroglycan itself have not been reported. Here we describe such a case, which represents a new disease class (i.e., primary dystroglycanopathy). The T192→M mutation in this case caused deficiencies in α-dystroglycan glycosylation and a marked reduction in α-dystroglycan's ability to bind extracellular-matrix components. Furthermore, our knock-in mouse model harboring the patient's mutation recapitulates the phenotype of secondary dystroglycanopathies in humans, supporting the view that dystroglycan is the main — and probably only — protein that is subject to the glycosylation abnormalities that cause muscular dystrophy.
Patients with dystroglycanopathy have a broad spectrum of disease phenotypes, with or without brain involvement. Limb-girdle muscular dystrophy with mental retardation was diagnosed in our patient according to the classification system established by Godfrey et al.13 Biochemical findings from analyses of mouse T190→M show that laminin-binding activity is considerably reduced (Figure 1 and Figure 2), suggesting that residual glycosylation may account for the relatively mild muscle phenotype, as compared with the findings in patients with other congenital muscular dystrophies.
Our patient had severe cognitive impairment, yet MRI revealed no gross structural abnormality in the brain.14 In more severe cases of human dystroglycanopathy, as well as in mice with a brain-specific Dag1 knockout, structural as well as functional brain abnormalities have been documented.3-6,9,10,16 Thus, it may be that residual laminin binding by human T192→M dystroglycan is sufficient for the development of the cerebral layer but not for the establishment of normal synaptic physiology. It remains unclear how dystroglycan contributes to synaptic physiology; however, reports that synaptic components possessing laminin globular domains play a fundamental role in establishing and maintaining synaptic function24,25 suggest that a reduction in the affinity of dystroglycan for synaptic proteins could be responsible for the neurologic phenotypes observed in the patient described here.
Our biochemical analyses show that the T192→M mutation impairs maturation of a specific modification of phosphorylated O-mannosyl glycans on α-dystroglycan (Figure 10 in the Supplementary Appendix). In the heart, T190→M α-dystroglycan maintains substantial laminin-binding activity despite a reduction in molecular weight consistent with that in skeletal muscle and brain (Figure 2 and Figure 3A), and this remaining activity may contribute to preserved cardiac function (Figure 8 in the Supplementary Appendix). The tissue variability in levels of α-dystroglycan's functional glycosylation remains unexplained, but there are several possible explanations (e.g., tissue-specific protein complexes might increase the affinity between dystroglycan and LARGE, or the enzymatic activity of LARGE might be enhanced in heart tissue). Further investigation will be required to delineate the tissue-specific mechanisms ensuring that phosphorylated O-mannosyl residues of α-dystroglycan mature into laminin-binding glycans.
In conclusion, we found a pathogenic missense mutation in DAG1 that selectively impairs further modification of phosphorylated O-mannosyl glycans on α-dystroglycan, leading to neuromuscular abnormalities. Our findings constitute evidence for the inclusion of DAG1 in the list of genes whose mutations cause muscular dystrophy and cognitive impairment in humans.
Supported in part by grants from the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (1U54NS053672, to Dr. Campbell), the Hacettepe University Research Fund (03.02.101.009, TÜBİTAK Project SBAG-1774, to Dr. Dinçer), the National Institutes of Health (AI45927, to Dr. Oldstone), the National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK 54759, to the University of Iowa Gene Transfer Vector Core), and the Muscular Dystrophy Campaign and Institute of Child Health Biomedical Research Centre (to Dr. Muntoni). Dr. Campbell is an investigator at the Howard Hughes Medical Institute.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Drs. Hara and Balci-Hayta contributed equally to this article.
We thank Harry Schachter, Michael Anderson, Michael Henry, and Charles Harata for their critical comments; Matthew Goddeeris, Colleen Campbell, Holly Harper, Sally Prouty, Mary Anderson, Keith Garringer, and members of the Campbell laboratory for their scientific contributions; Baoli Yang and Eileen Sweezer (University of Iowa Gene Targeting Core Facility) for generating the T190→M dystroglycan knock-in mice; Lydia Sorokin (Münster University) for the antibody against the laminin α1 chain (clone no. 317); and the University of Iowa Gene Transfer Vector Core for adenovirus purification.
Source Information
From the Departments of Molecular Physiology and Biophysics (Y.H., T.Y-M., M.K., D.B-V.B, T.W., J.S.S., R.W.C., A.A., K.P.C.), Neurology (K.P.C.), and Internal Medicine (K.P.C.), and the Howard Hughes Medical Institute (K.P.C.), University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City; the Departments of Medical Biology (B.B.-H., H.G., P.D.), Pediatric Pathology (B.T.), and Pediatric Neurology (H.T.), Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey; the Molecular Neurobiology Program, Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine, New York University Medical School, New York (S.J.B.); the Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland (S.K.); the Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, CA (M.B.A.O.); and the Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London (F.M.).
Address reprint requests to Dr. Campbell at the University of Iowa Roy J. and Lucille A. Carver College of Medicine, 285 Newton Rd., 4283 CBRB, Iowa City, IA 52242, or at kevin-campbell@uiowa.edu.
- References
References
1
Ibraghimov-Beskrovnaya O ,Ervasti JM ,Leveille CJ ,Slaughter CA ,Sernett SW ,Campbell KP . Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992;355:696-702
CrossRef | Web of Science | Medline2
Barresi R ,Campbell KP . Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006;119:199-207
CrossRef | Web of Science | Medline3
Michele DE ,Barresi R ,Kanagawa M , et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002;418:417-422
CrossRef | Web of Science | Medline4
Beltran-Valero de Bernabe D ,Currier S ,Steinbrecher A , et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002;71:1033-1043
CrossRef | Web of Science | Medline5
van Reeuwijk J ,Janssen M ,van den Elzen C , et al. POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 2005;42:907-912
CrossRef | Web of Science | Medline6
Yoshida A ,Kobayashi K ,Manya H , et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001;1:717-724
CrossRef | Web of Science | Medline7
Kobayashi K ,Nakahori Y ,Miyake M , et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998;394:388-392
CrossRef | Web of Science | Medline8
Brockington M ,Blake DJ ,Prandini P , et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan. Am J Hum Genet 2001;69:1198-1209
CrossRef | Web of Science | Medline9
Longman C ,Brockington M ,Torelli S , et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum Mol Genet 2003;12:2853-2861
CrossRef | Web of Science | Medline10
van Reeuwijk J ,Grewal PK ,Salih MA , et al. Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome. Hum Genet 2007;121:685-690
CrossRef | Web of Science | Medline11
Mercuri E ,Messina S ,Bruno C , et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology 2009;72:1802-1809
CrossRef | Web of Science | Medline12
Yoshida-Moriguchi T ,Yu L ,Stalnaker SH , et al. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 2010;327:88-92
CrossRef | Web of Science | Medline13
Godfrey C ,Clement E ,Mein R , et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007;130:2725-2735
CrossRef | Web of Science | Medline14
Dincer P ,Balci B ,Yuva Y , et al. A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of α-dystroglycan. Neuromuscul Disord 2003;13:771-778
CrossRef | Web of Science | Medline15
Kanagawa M ,Saito F ,Kunz S , et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 2004;117:953-964
CrossRef | Web of Science | Medline16
Moore SA ,Saito F ,Chen J , et al. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 2002;418:422-425
CrossRef | Web of Science | Medline17
Cote PD ,Moukhles H ,Lindenbaum M ,Carbonetto S . Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. Nat Genet 1999;23:338-342
CrossRef | Web of Science | Medline18
Nishimune H ,Valdez G ,Jarad G , et al. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. J Cell Biol 2008;182:1201-1215
CrossRef | Web of Science | Medline19
Michele DE ,Kabaeva Z ,Davis SL ,Weiss RM ,Campbell KP . Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ Res 2009;105:984-993
CrossRef | Web of Science | Medline20
Murakami T ,Hayashi YK ,Noguchi S , et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006;60:597-602
CrossRef | Web of Science | Medline21
Mercuri E ,Brockington M ,Straub V , et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003;53:537-542
CrossRef | Web of Science | Medline22
Grewal PK ,Holzfeind PJ ,Bittner RE ,Hewitt JE . Mutant glycosyltransferase and altered glycosylation of α-dystroglycan in the myodystrophy mouse. Nat Genet 2001;28:151-154
CrossRef | Web of Science | Medline23
Bozic D ,Sciandra F ,Lamba D ,Brancaccio A . The structure of the N-terminal region of murine skeletal muscle α-dystroglycan discloses a modular architecture. J Biol Chem 2004;279:44812-44816
CrossRef | Web of Science | Medline24
Sudhof TC . Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008;455:903-911
CrossRef | Web of Science | Medline25
Sato S ,Omori Y ,Katoh K , et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci 2008;11:923-931
CrossRef | Web of Science | Medline
- Citing Articles (38)
Citing Articles
1
Keren J. Carss, Elizabeth Stevens, A. Reghan Foley, Sebahattin Cirak, Moniek Riemersma, Silvia Torelli, Alexander Hoischen, Tobias Willer, Monique van Scherpenzeel, Steven A. Moore, Sonia Messina, Enrico Bertini, Carsten G. Bönnemann, Jose E. Abdenur, Carla M. Grosmann, Akanchha Kesari, Jaya Punetha, Ros Quinlivan, Leigh B. Waddell, Helen K. Young, Elizabeth Wraige, Shu Yau, Lina Brodd, Lucy Feng, Caroline Sewry, Daniel G. MacArthur, Kathryn N. North, Eric Hoffman, Derek L. Stemple, Matthew E. Hurles, Hans van Bokhoven, Kevin P. Campbell, Dirk J. Lefeber, Yung-Yao Lin, Francesco Muntoni. (2013) Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of α-Dystroglycan. The American Journal of Human Genetics
2
F. Rahimov, L. M. Kunkel. (2013) The cell biology of disease: Cellular and molecular mechanisms underlying muscular dystrophy. The Journal of Cell Biology 201:4, 499-510
3
K. Buysse, M. Riemersma, G. Powell, J. van Reeuwijk, D. Chitayat, T. Roscioli, E.-J. Kamsteeg, C. van den Elzen, E. van Beusekom, S. Blaser, R. Babul-Hirji, W. Halliday, G. J. Wright, D. L. Stemple, Y.-Y. Lin, D. J. Lefeber, H. van Bokhoven. (2013) Missense mutations in -1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Human Molecular Genetics 22:9, 1746-1754
4
M. Kanagawa, C.-C. Yu, C. Ito, S.-i. Fukada, M. Hozoji-Inada, T. Chiyo, A. Kuga, M. Matsuo, K. Sato, M. Yamaguchi, T. Ito, Y. Ohtsuka, Y. Katanosaka, Y. Miyagoe-Suzuki, K. Naruse, K. Kobayashi, T. Okada, S. Takeda, T. Toda. (2013) Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Human Molecular Genetics
5
Haiwei Xu, Yang Yang, Xiaotong Tang, Meina Zhao, Fucheng Liang, Pei Xu, Baoke Hou, Yan Xing, Xiaohang Bao, Xiaotang Fan. (2013) Bergmann Glia Function in Granule Cell Migration During Cerebellum Development. Molecular Neurobiology 47:2, 833-844
6
Ivette A. Martínez-Vieyra, Alejandra Vásquez-Limeta, Ricardo González-Ramírez, Sara L. Morales-Lázaro, Mónica Mondragón, Ricardo Mondragón, Arturo Ortega, Steve J. Winder, Bulmaro Cisneros. (2013) A role for β-dystroglycan in the organization and structure of the nucleus in myoblasts. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1833:3, 698-711
7
S. Cirak, A. R. Foley, R. Herrmann, T. Willer, S. Yau, E. Stevens, S. Torelli, L. Brodd, A. Kamynina, P. Vondracek, H. Roper, C. Longman, R. Korinthenberg, G. Marrosu, P. Nurnberg, , D. E. Michele, V. Plagnol, M. Hurles, S. A. Moore, C. A. Sewry, K. P. Campbell, T. Voit, F. Muntoni. (2013) ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain
8
Anna Sarkozy, Kate Bushby, Eugenio Mercuri. Muscular Dystrophies. In: Emery and Rimoin's Principles and Practice of Medical Genetics. Elsevier, 2013:1-58.
9
Hudson H. Freeze, Bobby G. Ng. Glycomics, Glycobiology, and Glyco-Medicine. In: Genomic and Personalized Medicine. Elsevier, 2013:173-191.
10
B. Eymard, N. Lévy. (2012) Diagnostic strategy for limb-girdle muscular dystrophies. Revue Neurologique 168:12, 919-926
11
Satomi Mitsuhashi, Peter B. Kang. (2012) Update on the Genetics of Limb Girdle Muscular Dystrophy. Seminars in Pediatric Neurology 19:4, 211-218
12
Sandrine Vuillaumier-Barrot, Céline Bouchet-Séraphin, Malika Chelbi, Louise Devisme, Samuel Quentin, Steven Gazal, Annie Laquerrière, Catherine Fallet-Bianco, Philippe Loget, Sylvie Odent, Dominique Carles, Anne Bazin, Jacqueline Aziza, Alix Clemenson, Fabien Guimiot, Maryse Bonnière, Sophie Monnot, Christine Bole-Feysot, Jean-Pierre Bernard, Laurence Loeuillet, Marie Gonzales, Koryna Socha, Bernard Grandchamp, Tania Attié-Bitach, Férechté Encha-Razavi, Nathalie Seta. (2012) Identification of Mutations in TMEM5 and ISPD as a Cause of Severe Cobblestone Lissencephaly. The American Journal of Human Genetics 91:6, 1135-1143
13
Christina M. Dobson, Samuel J. Hempel, Stephanie H. Stalnaker, Ryan Stuart, Lance Wells. (2012) O-Mannosylation and human disease. Cellular and Molecular Life Sciences
14
A. Gomez Toledo, M. Raducu, J. Cruces, J. Nilsson, A. Halim, G. Larson, U. Ruetschi, A. Grahn. (2012) O-Mannose and O-N-acetyl galactosamine glycosylation of mammalian -dystroglycan is conserved in a region-specific manner. Glycobiology 22:11, 1413-1423
15
Chris J. Moore, Steve J. Winder. (2012) The inside and out of dystroglycan post-translational modification. Neuromuscular Disorders 22:11, 959-965
16
Jacob Ross, Abigail Benn, Jacqueline Jonuschies, Luisa Boldrin, Francesco Muntoni, Jane E. Hewitt, Susan C. Brown, Jennifer E. Morgan. (2012) Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large myd Mouse. STEM CELLS 30:10, 2330-2341
17
Yung-Yao Lin. (2012) Muscle diseases in the zebrafish. Neuromuscular Disorders 22:8, 673-684
18
Adrian Waite, Susan C. Brown, Derek J. Blake. (2012) The dystrophin–glycoprotein complex in brain development and disease. Trends in Neurosciences 35:8, 487-496
19
Eugenio Mercuri, Francesco Muntoni. (2012) The ever-expanding spectrum of congenital muscular dystrophies. Annals of Neurology 72:1, 9-17
20
S. Saredi, A. Ardissone, A. Ruggieri, E. Mottarelli, L. Farina, R. Rinaldi, E. Silvestri, C. Gandioli, S. D'Arrigo, F. Salerno, L. Morandi, P. Grammatico, C. Pantaleoni, I. Moroni, M. Mora. (2012) Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease. Journal of the Neurological Sciences 318:1-2, 45-50
21
Susan C. Brown, Steve J. Winder. (2012) Dystroglycan and dystroglycanopathies: Report of the 187th ENMC Workshop 11–13 November 2011, Naarden, The Netherlands. Neuromuscular Disorders 22:7, 659-668
22
Tony Roscioli, Erik-Jan Kamsteeg, Karen Buysse, Isabelle Maystadt, Jeroen van Reeuwijk, Christa van den Elzen, Ellen van Beusekom, Moniek Riemersma, Rolph Pfundt, Lisenka E L M Vissers, Margit Schraders, Umut Altunoglu, Michael F Buckley, Han G Brunner, Bernard Grisart, Huiqing Zhou, Joris A Veltman, Christian Gilissen, Grazia M S Mancini, Paul Delrée, Michèl A Willemsen, Danijela Petković Ramadža, David Chitayat, Christopher Bennett, Eamonn Sheridan, Els A J Peeters, Gita M B Tan-Sindhunata, Christine E de Die-Smulders, Koenraad Devriendt, Hülya Kayserili, Osama Abd El-Fattah El-Hashash, Derek L Stemple, Dirk J Lefeber, Yung-Yao Lin, Hans van Bokhoven. (2012) Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan. Nature Genetics
23
Saddam M. Muthana, Christopher T. Campbell, Jeffrey C. Gildersleeve. (2012) Modifications of Glycans: Biological Significance and Therapeutic Opportunities. ACS Chemical Biology 7:1, 31-43
24
Virginie Carmignac, Madeleine Durbeej. (2012) Cell-matrix interactions in muscle disease. The Journal of Pathology 226:2, 200-218
25
Andrea Brancaccio. (2012) DAG1, no gene for RNA regulation?. Gene
26
Roger B. Sher, Gregory A. Cox, Cheryl Ackert-Bicknell. Development and Disease of Mouse Muscular and Skeletal Systems. In: The Laboratory Mouse. Elsevier, 2012:209-239.
27
Yvonne M. Kobayashi, Kevin P. Campbell. Skeletal Muscle Dystrophin-Glycoprotein Complex and Muscular Dystrophy. In: Muscle. Elsevier, 2012:935-942.
28
Simona Morlacchi, Francesca Sciandra, Maria Bigotti, Manuela Bozzi, Wolfgang Hübner, Antonio Galtieri, Bruno Giardina, Andrea Brancaccio. (2012) Insertion of a myc-tag within α-dystroglycan domains improves its biochemical and microscopic detection. BMC Biochemistry 13:1, 14
29
A. J. Wood, J. S. Muller, C. D. Jepson, S. H. Laval, H. Lochmuller, K. Bushby, R. Barresi, V. Straub. (2011) Abnormal vascular development in zebrafish models for fukutin and FKRP deficiency. Human Molecular Genetics 20:24, 4879-4890
30
Neha Singhal, Paul T. Martin. (2011) Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Developmental Neurobiology 71:11, 982-1005
31
Y. Hara, M. Kanagawa, S. Kunz, T. Yoshida-Moriguchi, J. S. Satz, Y. M. Kobayashi, Z. Zhu, S. J. Burden, M. B. A. Oldstone, K. P. Campbell. (2011) Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection. Proceedings of the National Academy of Sciences 108:42, 17426-17431
32
Francesco Muntoni, Silvia Torelli, Dominic J. Wells, Susan C. Brown. (2011) Muscular dystrophies due to glycosylation defects. Current Opinion in Neurology 24:5, 437-442
33
Vincenzo Nigro, Stefania Aurino, Giulio Piluso. (2011) Limb girdle muscular dystrophies. Current Opinion in Neurology 24:5, 429-436
34
Camilla Hesse, Inger Johansson, Niklas Mattsson, Daniel Bremell, Ulf Andreasson, Adnan Halim, Rolf Anckarsäter, Kaj Blennow, Henrik Anckarsäter, Henrik Zetterberg, Göran Larson, Lars Hagberg, Ammi Grahn. (2011) The N-terminal domain of α-dystroglycan, released as a 38kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. Biochemical and Biophysical Research Communications 412:3, 494-499
35
Z. Kabaeva, K. E. Meekhof, D. E. Michele. (2011) Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function. Human Molecular Genetics 20:17, 3346-3355
36
Rita Barresi. (2011) From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies. Skeletal Muscle 1:1, 24
37
Harvey B. Sarnat. Muscular Dystrophies. In: Nelson Textbook of Pediatrics. Elsevier, 2011:2119-2129.
38
Jessica D. Gumerson, Daniel E. Michele. (2011) The Dystrophin-Glycoprotein Complex in the Prevention of Muscle Damage. Journal of Biomedicine and Biotechnology 2011, 1-13
